Related Experiment Video
Updated: Sep 13, 2025
A Luciferase-fluorescent Reporter Influenza Virus for Live Imaging and Quantification of Viral Infection
Published on: August 14, 2019
Recommendations for Prevention and Control of Influenza in Children, 2025-2026: Technical Report
Insights
Annual influenza vaccination is recommended for all children aged 6 months and older to prevent and treat influenza. This strategy protects both children and the community, with updated guidance for the 2025-2026 season.
Area of Science:
- Pediatrics
- Infectious Diseases
- Vaccinology
Background:
- Influenza poses a significant risk to children, causing morbidity and mortality.
- Annual influenza vaccination is a key public health strategy for pediatric populations.
- The American Academy of Pediatrics provides guidance for the 2025-2026 influenza season.
Purpose of the Study:
- To provide the rationale for the American Academy of Pediatrics' influenza vaccine recommendations for children.
- To summarize current data on influenza seasons, vaccine effectiveness, and coverage in children.
- To offer detailed guidance on influenza vaccine and antiviral medication use for the 2025-2026 season.
Main Methods:
- Review of recent influenza season data, including pediatric morbidity and mortality.
- Analysis of influenza vaccine effectiveness and vaccination coverage rates.
- Compilation of information on available influenza vaccines, diagnostic testing, and antiviral treatments.
Main Results:
- Influenza vaccination is crucial for protecting children and the community.
- Guidance covers vaccine storage, administration, and implementation strategies.
- Information on inactivated and live attenuated influenza vaccines is provided.
Conclusions:
- Annual influenza vaccination is recommended for all children without contraindications starting at 6 months of age.
- Antiviral medications are recommended for treatment and chemoprophylaxis.
- Strategies to enhance vaccine uptake are emphasized for the 2025-2026 influenza season.
Abstract:
This technical report accompanies the recommendations of the American Academy of Pediatrics for the routine use of influenza vaccine and antiviral medications in the prevention and treatment of influenza in children during the 2025-2026 influenza season. The rationale for the American Academy of Pediatrics recommendation for annual influenza vaccination of all children without medical contraindications starting at 6 months of age is provided. Influenza vaccination is an important strategy for protecting children and the broader community against influenza. This technical report summarizes recent influenza seasons, morbidity and mortality in children, vaccine effectiveness, and vaccination coverage and provides detailed guidance on vaccine storage, administration, and implementation. The report also provides a brief background on inactivated (non-live) and live attenuated influenza vaccines, available vaccines for the 2025-2026 influenza season, vaccination during pregnancy and breastfeeding, diagnostic testing for influenza, and antiviral medications for treatment and chemoprophylaxis. Strategies to promote vaccine uptake are emphasized.
Related Concept Videos
01:51Vaccinations
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:25Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
01:22Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...